Baiyang Pharmaceutical (301015)
SZSE · 301015
Record TypeProfile record
Record UpdatedJun 4, 2026
Market Cap$10.9B
Revenue$7.4B
Employees2493
Listed OnSZSE
Ticker301015
CEO / ExecMr. Gang Fu
HeadquartersQingdao
MarketMainland China
Websitewww.baheal.cn
Overview
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tum
Source Note
This record combines exchange fields with selected profile enrichment. Treat market data, leadership and financial figures as directional unless verified against company filings, exchange announcements or the issuer's own disclosures.